• Conditions and diseases

  • Blood and immune system •
  • Cancer •
  • Cardiovascular •
  • Central nervous system •
  • Digestive system •
  • Ear and nose •
  • Endocrine, nutritional and metabolic •
  • Eye •
  • Gynaecology, pregnancy and birth •
  • Infectious diseases •
  • Injuries, accidents and wounds •
  • Mental health and behavioural conditions •
  • Mouth and dental •
  • Musculoskeletal •
  • Respiratory •
  • Skin •
  • Urogenital

• Public health

  • Accidents and injuries •
  • Alcohol •
  • Behaviour change •
  • Cancer •
  • Cardiovascular disease •
  • Child health •
  • Child social care •
  • Chronic illness •
  • Diabetes •
  • Drugs •
  • Environmental health •
  • Infectious diseases •
  • Maternal health •
  • Mental health •
  • Non-communicable diseases •
  • Obesity and diet •
  • Occupational health •
  • Older people •
  • Physical activity •
  • Sexual health •
  • Smoking and tobacco •
  • Transport •
  • Vaccine preventable diseases •
  • Working with and involving communities

• Treatments, Procedures and Devices

  • Bones and joint surgery •
  • Cardiovascular surgery •
  • Cardiovascular system drug treatments •
  • Clinical devices •
  • Diagnostic imaging •
  • Diagnostic procedures •
  • Digestive tract and other abdominal organs surgery •
  • Drug treatments •
  • Endocrine system and breast surgery •
  • Eye surgery •
  • Nervous system surgery •
  • Radiotherapy •
  • Screening •
  • Surgical procedures •
  • Therapeutic procedures •
  • Tissue and organ donation •
  • Urogenital surgery

• Guidance by type

  • Clinical Guidelines •
  • Technology appraisals •
  • Public health guidance •
  • Diagnostics guidance •
  • Interventional procedures guidance •
  • Medical technologies guidance •
  • Cancer service guidance •
  • Quality standards

• Guidance by date

  • View the guidance by date published

About NICE guidance Close

Navigation

• NICE guidance

• Find guidance
• NICE Pathways
• Latest guidance
• Guidance by type
• Guidance in development
• How guidance is produced
• NICE guidance research recommendations
• Guidance for patients and public
• Other publications
• Patient safety solutions pilot
• Quality standards

Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib (review)

Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours (part review of TA86)

Status:	History
Expected date of issue:	November 2010
Wave:	R
Process:	MTA
Topic area: Cancer Digestive system

Project team | Schedule | Stakeholders | Key documents

 

NICE project team

Executive Lead:	Peter Littlejohns
Technical Lead:	Joao Vieira
Communications manager:	Alice Law
Project manager:	Jeremy Powell
Assessment group:	Aberdeen Health Technology Assessment Group

Top

 

Provisional schedule

Consultation on draft scope by stakeholders:	25 June 2009
Closing date for invited submissions / evidence submission:	23 November 2009
1st appraisal committee meeting:	02 June 2010
2nd appraisal committee meeting:	04 August 2010

Top

 

Consultees and commentators

Consultees Commentators (no right to submit or appeal) Manufacturers/sponsors Novartis (imatinib) Patient/carer groups Beating Bowel Cancer Bowel Cancer UK GIST Support UK Macmillan Cancer Support Rarer Cancers Forum Sarcoma UK Professional groups Cancer Research UK Royal College of Nursing Royal College of Pathologists Royal College of Physicians, Medical Oncology Joint Special Committee United Kingdom Oncology Nursing Society Others Department of Health Welsh Assembly Government General Department of Health, Social Services and Public Safety for Northern Ireland NHS Quality Improvement Scotland Comparator manufacturer(s) Pfizer (sunitinib) Relevant research groups National Cancer Research Institute Assessment Group Aberdeen Health Technology Assessment Group National Institute for Health Research Health Technology Assessment Programme Associated Guideline Groups National Collaborating Centre for Cancer

Top

 

Key documents

Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib (review): Equality impact assessment 21 February 2011 Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib (review): rejected appeal 24 November 2010 Gastro-intestinal stromal tumours (unresectable/metastatic) - imatinib (review): final appraisal determination 16 September 2010 Gastro-intestinal stromal tumours (unresectable/metastatic) - imatinib (review): appraisal consultation 29 June 2010 Gastro-intestinal stromal tumours (unresectable/metastatic) - imatinib (review): assessment report 28 April 2010 Gastro-intestinal stromal tumours (unresectable/metastatic) - imatinib (review): final protocol 17 November 2009 Gastro-intestinal stromal tumours (unresectable/metastatic) - imatinib (review): final scope 21 August 2009 Gastro-intestinal stromal tumours (unresectable/metastatic) - imatinib (review): final matrix of consultee and commentators 21 August 2009 Gastro-intestinal stromal tumours (unresectable/metastatic) - imatinib (review): Institute's response to consultee and commentator comments on the draft scope 21 August 2009 Gastro-intestinal stromal tumours (unresectable/metastatic) - imatinib (review): draft scope 02 July 2009 Gastro-intestinal stromal tumours (unresectable/metastatic) - imatinib (review): provisional matrix of consultee and commentators 02 July 2009

This page was last updated: 21 February 2011